Refined peptide HLA-B(*)3501 binding motif reveals differences in 9-mer to 11-mer peptide binding

Christian Schönbach, Kiyoshi Miwa, Masaaki Ibe, Hajime Shiga, Kiyoshi Nokihara, Masafumi Takiguchi

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

HLA-B(*)3501 is associated with subacute thyroiditis and fast progression of AIDS. An important prerequisite to investigate the T-cell recognition of HLA-B(*)3501-restricted antigens is the characterization of peptide-HLA-B(*)3501 interactions. In this study, peptide-HLA-B(*)3501 interactions were determined in quantitative peptide binding assays. The results were statistically analyzed to evaluate the influence of both anchor and nonanchor positions and the predictability of peptide binding. The binding data demonstrated that all anchor residues at position 2 and the C-terminus found in 9-mers functioned equally as anchors in 10-mers and 11-mers. These minimum requirements of peptide binding were refined by assessing positive and negative effects of nonanchor residues. Aliphatic hydrophobic residues at positions 3, 5, and 8 of 10-mers and position 3 of 11-mers significantly enhanced HLA-B(*)3501 binding. Similar effects rendered aromatic, bulky residues, acidic or polar residues of 11-mers at position 1 as well as at positions 4, 8, and 10, respectively. Negative effects were observed for residues carrying positively charged side-chains at position 7 of 11-mers. The refined HLA-B(*)3501 peptide binding motifs enhanced the identification of potential T-cell epitopes. The disparity between positive effects at the middle and C-terminal part (positions 5-8 and 10) of 11-mers and shorter peptides supports the extrusion of 11-mer residues at positions 5, 6, and 7, away from the HLA-B(*)3501 binding cleft.

Original languageEnglish
Pages (from-to)121-129
Number of pages9
JournalImmunogenetics
Volume45
Issue number2
DOIs
Publication statusPublished - 1996
Externally publishedYes

Fingerprint

HLA-B Antigens
Peptides
Subacute Thyroiditis
T-Lymphocyte Epitopes
peptide B
Acquired Immunodeficiency Syndrome
T-Lymphocytes

ASJC Scopus subject areas

  • Immunology
  • Genetics

Cite this

Refined peptide HLA-B(*)3501 binding motif reveals differences in 9-mer to 11-mer peptide binding. / Schönbach, Christian; Miwa, Kiyoshi; Ibe, Masaaki; Shiga, Hajime; Nokihara, Kiyoshi; Takiguchi, Masafumi.

In: Immunogenetics, Vol. 45, No. 2, 1996, p. 121-129.

Research output: Contribution to journalArticle

Schönbach, Christian ; Miwa, Kiyoshi ; Ibe, Masaaki ; Shiga, Hajime ; Nokihara, Kiyoshi ; Takiguchi, Masafumi. / Refined peptide HLA-B(*)3501 binding motif reveals differences in 9-mer to 11-mer peptide binding. In: Immunogenetics. 1996 ; Vol. 45, No. 2. pp. 121-129.
@article{d01dc807d8034932b666996816f0c2fb,
title = "Refined peptide HLA-B(*)3501 binding motif reveals differences in 9-mer to 11-mer peptide binding",
abstract = "HLA-B(*)3501 is associated with subacute thyroiditis and fast progression of AIDS. An important prerequisite to investigate the T-cell recognition of HLA-B(*)3501-restricted antigens is the characterization of peptide-HLA-B(*)3501 interactions. In this study, peptide-HLA-B(*)3501 interactions were determined in quantitative peptide binding assays. The results were statistically analyzed to evaluate the influence of both anchor and nonanchor positions and the predictability of peptide binding. The binding data demonstrated that all anchor residues at position 2 and the C-terminus found in 9-mers functioned equally as anchors in 10-mers and 11-mers. These minimum requirements of peptide binding were refined by assessing positive and negative effects of nonanchor residues. Aliphatic hydrophobic residues at positions 3, 5, and 8 of 10-mers and position 3 of 11-mers significantly enhanced HLA-B(*)3501 binding. Similar effects rendered aromatic, bulky residues, acidic or polar residues of 11-mers at position 1 as well as at positions 4, 8, and 10, respectively. Negative effects were observed for residues carrying positively charged side-chains at position 7 of 11-mers. The refined HLA-B(*)3501 peptide binding motifs enhanced the identification of potential T-cell epitopes. The disparity between positive effects at the middle and C-terminal part (positions 5-8 and 10) of 11-mers and shorter peptides supports the extrusion of 11-mer residues at positions 5, 6, and 7, away from the HLA-B(*)3501 binding cleft.",
author = "Christian Sch{\"o}nbach and Kiyoshi Miwa and Masaaki Ibe and Hajime Shiga and Kiyoshi Nokihara and Masafumi Takiguchi",
year = "1996",
doi = "10.1007/s002510050179",
language = "English",
volume = "45",
pages = "121--129",
journal = "Immunogenetics",
issn = "0093-7711",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Refined peptide HLA-B(*)3501 binding motif reveals differences in 9-mer to 11-mer peptide binding

AU - Schönbach, Christian

AU - Miwa, Kiyoshi

AU - Ibe, Masaaki

AU - Shiga, Hajime

AU - Nokihara, Kiyoshi

AU - Takiguchi, Masafumi

PY - 1996

Y1 - 1996

N2 - HLA-B(*)3501 is associated with subacute thyroiditis and fast progression of AIDS. An important prerequisite to investigate the T-cell recognition of HLA-B(*)3501-restricted antigens is the characterization of peptide-HLA-B(*)3501 interactions. In this study, peptide-HLA-B(*)3501 interactions were determined in quantitative peptide binding assays. The results were statistically analyzed to evaluate the influence of both anchor and nonanchor positions and the predictability of peptide binding. The binding data demonstrated that all anchor residues at position 2 and the C-terminus found in 9-mers functioned equally as anchors in 10-mers and 11-mers. These minimum requirements of peptide binding were refined by assessing positive and negative effects of nonanchor residues. Aliphatic hydrophobic residues at positions 3, 5, and 8 of 10-mers and position 3 of 11-mers significantly enhanced HLA-B(*)3501 binding. Similar effects rendered aromatic, bulky residues, acidic or polar residues of 11-mers at position 1 as well as at positions 4, 8, and 10, respectively. Negative effects were observed for residues carrying positively charged side-chains at position 7 of 11-mers. The refined HLA-B(*)3501 peptide binding motifs enhanced the identification of potential T-cell epitopes. The disparity between positive effects at the middle and C-terminal part (positions 5-8 and 10) of 11-mers and shorter peptides supports the extrusion of 11-mer residues at positions 5, 6, and 7, away from the HLA-B(*)3501 binding cleft.

AB - HLA-B(*)3501 is associated with subacute thyroiditis and fast progression of AIDS. An important prerequisite to investigate the T-cell recognition of HLA-B(*)3501-restricted antigens is the characterization of peptide-HLA-B(*)3501 interactions. In this study, peptide-HLA-B(*)3501 interactions were determined in quantitative peptide binding assays. The results were statistically analyzed to evaluate the influence of both anchor and nonanchor positions and the predictability of peptide binding. The binding data demonstrated that all anchor residues at position 2 and the C-terminus found in 9-mers functioned equally as anchors in 10-mers and 11-mers. These minimum requirements of peptide binding were refined by assessing positive and negative effects of nonanchor residues. Aliphatic hydrophobic residues at positions 3, 5, and 8 of 10-mers and position 3 of 11-mers significantly enhanced HLA-B(*)3501 binding. Similar effects rendered aromatic, bulky residues, acidic or polar residues of 11-mers at position 1 as well as at positions 4, 8, and 10, respectively. Negative effects were observed for residues carrying positively charged side-chains at position 7 of 11-mers. The refined HLA-B(*)3501 peptide binding motifs enhanced the identification of potential T-cell epitopes. The disparity between positive effects at the middle and C-terminal part (positions 5-8 and 10) of 11-mers and shorter peptides supports the extrusion of 11-mer residues at positions 5, 6, and 7, away from the HLA-B(*)3501 binding cleft.

UR - http://www.scopus.com/inward/record.url?scp=0029841747&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029841747&partnerID=8YFLogxK

U2 - 10.1007/s002510050179

DO - 10.1007/s002510050179

M3 - Article

C2 - 8952961

AN - SCOPUS:0029841747

VL - 45

SP - 121

EP - 129

JO - Immunogenetics

JF - Immunogenetics

SN - 0093-7711

IS - 2

ER -